Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $117
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.
Last updated: 2026-11-19 07:45:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CG Oncology, Inc. (CGON) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $79.98, with a market capitalization of $7.05B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $37.01 to $93.95. This page covers its latest market performance, valuation, price trends and company information.
$7.05B | |
$79.13 | |
$81.97 | |
$77.38 | |
$78.94 | |
1.50M | |
1.20M | |
-- | |
$93.95 | |
$37.01 | |
-- | |
2026-09-30 |
CG Oncology, Inc. (CGON) last closed at $79.98 as of 2026-11-19 01:00:00, up 1.28% ($1.01) from the previous close of $78.94.
During the latest regular trading session, CGON traded between $77.38 and $81.97, with a volume of 1.50M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, CG Oncology, Inc. (CGON) moved from $72.64 to $79.98, representing a gain of 10.10% ($7.33).
The stock traded between $67.43 and $93.95 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 3.02 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 75.5%
CGON is currently trading at $79.98, placing it 75.5% of the way from its 52-week low of $37.01 to its 52-week high of $93.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to CG Oncology, Inc. and CGON stock.
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $96 to $113.
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $85 to $100.
RBC Capital analyst Leonid Timashev downgrades CG Oncology (NASDAQ:CGON) from Outperform to Sector Perform and raises the price target from $80 to $97.
Wall Street analysts raised price targets for CG Oncology, Viatris, Rubrik, Allarity, IDACORP, Tyson Foods and Range Resources.
Eligible investors can buy real shares of CG Oncology, Inc. (CGON) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CGON, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CGON shares and USD.
CGON Shares to USD
1.00 CGON shares = 79.975 USD
Calculations are estimates based on the latest available price and are for reference only.